Cannabinoid modulation of perivascular sympathetic and sensory neuro-transmission

Current Vascular Pharmacology

Volumn 7, Issue 1, 2009, Pages 15-25

  Ralevic, Vera ^a   Kendall, David A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anandamide; Autonomic nervous system; Cannabinoids; Peripheral nervous system; Sensory nerves; Sympathetic nerves; Vanilloids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; N(G) NITROARGININE METHYL ESTER; RIMONABANT; TETRAHYDROCANNABINOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VANILLOID RECEPTOR 1; CANNABINOID RECEPTOR; TRPV1 RECEPTOR; VANILLOID RECEPTOR;

ADRENERGIC TRANSMISSION; BLOOD VESSEL INNERVATION; CENTRAL NERVOUS SYSTEM; DRUG TARGETING; HUMAN; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; RECEPTOR DOWN REGULATION; REVIEW; SENSORY GANGLION; SENSORY NERVE; SENSORY NERVE CONDUCTION; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION; ADRENERGIC SYSTEM; ANIMAL; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; CANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; TRPV CATION CHANNELS;

EID: 61549104157     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109787354114     Document Type: Review

References (124)

1. Pertwee RG. The evidence for the existence of cannabinoid receptors. Gen Pharmacol 1993; 24: 811-24.
2. 2 receptors. Pharmacol Ther 1997; 74: 129-80.
3. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
4. 2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-41.
5. Wagner JA, Varga K, Járai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33: 429-34.
6. Kunos G, Batkai S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 2001; 26: 1015-21.
7. White R, Ho W-SV, Bottrill FE, Ford WR, Hiley CR. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 2001; 134: 921-9.
8. Baker D, Pryce G, Davis WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27: 1-4.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-9.
10. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
11. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129: 227-30.
12. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351: 817-24.
13. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 99: 8400-5.
14. 2 cannabinoid receptor-independent mechanism. J Neuroscience 2002; 22: 4720-7.
15. 9-Tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed. Br J Pharmacol 2007; 152: 709-716.
16. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002; 95: 191-202.
17. Randall MD, Kendall DA, O' Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004; 142: 20-6.
18. Ralevic V, Kendall DA, Randall MD, Smart D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 2002; 71: 2577-94.
19. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-8.
20. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998; 359: 1-18.
21. Giuffrida A, Bletramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298: 7-14.
22. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
23. 2 receptors. Science 2005; 310: 329-332.
24. 2 receptors in brain. Annals New York Academy of Sciences 2006; 1074: 514-536.
25. Hillsley K, McCaul C, Aerssens J, Peeters PJ, Gijsen H, Moechars D, et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 2007; 19: 769-777.
26. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 2001; 20: 7033-40.
27. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-211.
28. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
29. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288: 306-13.
30. Maggi CA, Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen Pharmacol 1988; 19: 1-43.
31. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-7.
32. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Ann Rev Neurosci 2001; 24: 487-517.
33. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991; 43: 143-201.
34. Holzer P. Neural injury, repair, and adaptation in the GI tract II. The elusive action of capsaicin on the vagus nerve. Am J Physiol 1998; 275: G8-13.
35. Holzer P. Peptidergic sensory neurons in the control of vascular functions: mechanisms and significance in the cutaneous and splanchnic vascular beds. Rev Physiol Pharmacol 1992; 121: 49-146.
36. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000; 97: 3655-60.
37. Ralevic V, Kendall DA, Zygmunt PM, Movahed P, Högestätt ED. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed. Br J Pharmacol 2000; 130: 1483-8.
38. Olah Z, Karai L, Iadarola MJ. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 2001; 276: 31163-70.
39. DePetrocellis L, Bisogno T, Maccarone M, Dais JB, Finazzi-Agro A, DiMarzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276: 12856-63.
40. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 2001; 132: 631-40.
41. Jung J, Hwang SW, Kwak J, Lee S-Y, Kang C-J, Kim WB, et al. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J Neurosci 1999; 19: 529-38.
42. Craib SJ, Ellington HC, Pertwee RG, Ross RA. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 2001; 134: 30-7.
43. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000; 408: 985-90.
44. Jerman JC, Brough SJ, Prinjha R, Harries MH, Davis JB, Smart D. Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology. Br J Pharmacol 2000; 130: 916-22.
45. Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, Cairns W, et al. Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur J Pharmacol 2001; 417: 51-8.
46. Ralevic V, Kendall DA, Jerman JC, Middlemiss DN, Smart D. Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 2001; 424: 211-9.
47. Hayes P, Meadows HJ, Gunthorpe MJ, Harries MH, Duckworth MD, Cairns W, et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2001; 88: 207-12.
48. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 2001; 534: 813-25.
49. Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG. Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. Eur J Pharmacol 2001; 423: 121-5.
50. Hwang SW, Cho H, Kwak J, Lee S-Y, Kang C-J, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000; 97: 6155-60.
51. Piomelli D. The ligand that came from within. Trends Pharmacol Sci 2001; 22: 17-9.
52. Millns PJ, Chapman V, Kendall DA. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion cells. Br J Pharmacol 2001; 132: 969-71.
53. Minke B, Cook B. TRP channel proteins and signal transduction. Physiol Rev 2002; 82: 429-72.
54. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426: 517-24.
55. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152: 576-582.
56. 9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 2005; 337: 824-31.
57. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996; 118: 2023-8.
58. 2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 1998; 82: 1131-49.
59. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339: 53-61.
60. Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 1999; 520: 539-50.
61. Molderings GJ, Likungu J, Göthert M. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmied Arch Pharmacol 1999; 360: 157-64.
62. Ralevic V, Kendall DA. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 2002; 444: 171-81.
63. Pakdeechote P, Dunn WR, Ralevic V. Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed. Br J Pharmacol 2007; 152: 725-733.
64. Lay L, Angus JA, Wright CE. Pharmacological characterisation of cannabinoid CB1 receptors in the rat and mouse. Eur J Pharmacol 2000; 391: 151-61.
65. Molderings GJ, Göthert M. Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fund Clin Pharmacol 1998; 12: 388-97.
66. Molderings GJ, Göthert M. Imidazoline binding sites and receptors in cardiovascular tissue. Gen Pharmacol 1999; 32: 17-22.
67. Burnstock G. Co-transmission. The fifth Heymans memorial lecture. Arch Int Pharmacodyn Ther 1990; 304: 7-33.
68. Burnstock G, Ralevic V. Cotransmission. In: The Pharmacology of Vascular Smooth Muscle. Garland CJ and Angus J. (Eds.). Oxford University Press, Oxford, 1996; 210-32.
69. Ellis JL, Burnstock G. Angiotensin modulation of adrenergic and purinergic cotransmission in the guinea-pig vas deferens. Br J Pharmacol 1989; 97: 1157-64.
70. Von Kügelgen I, Starke K. Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol Sci 1991; 12: 319-24.
71. Driessen B, von Kugelgen I, Starke K. P1-purinoceptor-mediated modulation of neural noradrenaline and ATP release in guinea-pig vas deferens. Naunyn Schmiedeberg's Arch Pharmacol 1994; 350: 42-8.
72. Todorov LD, Mihaylova-Todorova S, Craviso GL, Bjur RA, Westfall DP. Evidence for the differential release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea-pig vas deferens. J Physiol 1996; 496: 731-48.
73. Dunn WR, Brock JK, Hardy TA. Electrochemical and electrophysiological characterization of neurotransmitter release from sympathetic nerves supplying rat mesenteric arteries. Br J Pharmacol 1999; 128: 174-80.
74. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100: 1538-46.
75. Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 1999; 126: 457-66.
76. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anaesthetized and conscious normotensive and hypertensive rats. Hypertension 1997; 29: 1204-10.
77. 1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 2001; 364: 233-41.
78. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995; 278: 279-83.
79. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetised rats. Hypertension 1996; 28: 682-6.
80. Malinowska B, Godlewski G, Bucher B, Schliker E. Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn-Schmied Arch Pharmacol 1997; 356: 197-202.
81. 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 1996; 28: 332-6.
82. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci 1999; 65: 665-73.
83. Fuentes JA, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J. Cannabinoids as potential new analgesics. Life Sci 1999; 65: 675-85.
84. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B 2001; 356: 381-408.
85. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
86. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. Curr Op Neurobiol 2002; 12: 372-9.
87. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. APS J 2006; 8: E693-708.
88. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999; 90: 923-31.
89. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92: 1171-5.
90. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacol 2001; 40: 221-32.
91. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006; 23: 1530-8.
92. Kawasaki H, Takasaki K, Saito A, Goto K. Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 1988; 335: 164-7.
93. Duncan M, Kendall DA, Ralevic V. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. J Pharmacol Exp Ther 2004; 311: 411-9.
94. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000; 100: 685-8.
95. i/o linked receptor. Br J Pharmacol 2004; 142: 509-18.
96. 1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
97. Duncan M, Kendall DA, Ralevic V. The effects of ruthenium red on the inhibitory actions of noladin ether, THC and HU210 on sensory neurotransmission in the rat isolated mesenteric arterial bed. 1st European Workshop on Cannabinoid Research, http://www.ucm.es/info/ seic-web/abstract-book.pdf.
98. 1 receptors. Pain 1998; 75: 111-9.
99. Beltramo M, Piomelli D. Anandamide transport inhibition by the vanilloid agonist olvanil. Eur J Pharmacol 1999; 364: 75-8.
100. Morisset V, Ahluwalia J, Nagy I, Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur J Pharmacol 2001; 429: 93-100.
101. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001; 21: 1104-9.
102. Harris D, McCulloch AI, Kendall DA, Randall MD. Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 2002; 539: 893-902.
103. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999; 264: 258-67.
104. Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 2001; 418: 117-25.
105. 9-tetrahydrocannabinol attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed. Br J Pharmacol 2003; 138: 214P.
106. Smith PJW, McQueen DS. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 2001; 134: 655-63.
107. Ledent C, Valverde O, Cossu C, Petitet F, Aubert LF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced additive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-4.
108. Vanheel B, Van de Voorde J. Regional differences in anandamide-and methanandamide-induced membrane potential changes in rat mesenteric arteries. J Pharmacol Exp Ther 2001; 296: 322-8.
109. Di Marzo V, Fontana A, Cadas H, Scinelli S, Cimino G, Schwartz J-C, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
110. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 1999; 65: 645-55.
111. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-24.
112. Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 2001; 425: 189-96.
113. Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 2003; 84: 585-91.
114. 2+-induced relaxation. J Pharmacol Exp Ther 1999; 289: 245-50.
115. 1 receptor-deficient mice. Hypertension 2002; 39: 251-7.
116. Bonhaus DW, Chang LK, Kwan J, Martin GR. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 1998; 287: 884-8.
117. Smart D, Jerman JC. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci 2000; 21: 134.
118. Ralevic V, Karoon P, Burnstock G. Long-term sensory denervation by neonatal capsaicin treatment augments sympathetic neurotransmission in rat mesenteric arteries by increasing levels of noradrenaline and selectively enhancing postjunctional actions. J Pharmacol Exp Ther 1995; 274: 64-71.
119. Ziganshin AU, Ralevic V, Burnstock G. Contractility of urinary bladder and vas deferens after sensory denervation by capsaicin treatment of newborn rats. Br J Pharmacol 1995; 114: 166-70.
120. Wardle KA, Furey G, Sanger GJ. Pharmacological characterization of the vanilloid receptor in the rat isolated vas deferens. J Pharm Pharmacol 1996; 48: 285-91.
121. Szabo B, Nordheim U, Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 2001; 297: 819-26.
122. 1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta. Naunyn-Schmiedeberg's Arch Pharmacol 2005; 372: 139-46.
123. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and α-adrenoceptors in mouse tissues. Br J Pharmacol 2000; 130: 321-30.
124. 3H]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors. J Neurochem 2000; 75: 2087-94.